We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Randox Laboratories

Provides global diagnostic solutions for hospital laboratories, forensic laboratories, research laboratories, pharmac... read more Featured Products: More products

Download Mobile App





Randox Launches Mobile COVID-19 Lab that Processes 1000 Samples per Day and Generates Results in 1-3 Hours

By LabMedica International staff writers
Posted on 14 Dec 2020
Print article
Image: A new Mobile Laboratory Service from Randox (Photo courtesy of Randox Laboratories)
Image: A new Mobile Laboratory Service from Randox (Photo courtesy of Randox Laboratories)
Randox Laboratories (Crumlin, UK) has unveiled a new Mobile Laboratory Service which will offer rapid and reliable COVID-19 workplace testing.

The service from Randox, which is the largest COVID-19 testing provider in the UK and Ireland, and a partner in the UK Government’s National COVID-19 Testing Program, uses gold standard PCR technology to generate results in one-three hours. Each Mobile Laboratory will be capable of processing up to 1,000 samples per day, to allow employers to uphold COVID safety within the workplace and maintain maximum output. As part of the Randox Mobile COVID-19 testing service, a team of healthcare professionals will collect the samples on site, and a Laboratory Technician will subsequently expedite the sample and reports the results.

The state-of-the-art Randox Mobile COVID-19 Laboratory comes fully staffed and stocked for testing, and is suitable for any and all industries. It can be booked to attend any location within the UK, providing a unique testing solution bespoke to each client’s needs.

“As the nation continues to navigate the working challenges caused by the COVID-19 pandemic, an increasing number of organizations will want to implement a COVID-19 testing regime so that they can sustain safe working environments,” said Dr. Peter FitzGerald, Randox Managing Director. “With this in mind we continue to expand our portfolio of bespoke testing products and services, and our latest addition, the Mobile Testing Laboratory, in conjunction with our work within the National Testing Programe, brings us one step closer to a timely return to a more normal society.”

“Since a new study by researchers at the University College London revealed that 86% of people who tested positive for COVID-19 did not have virus symptoms, frequent screening of asymptomatic patients, is vital to identify any hotspots and limit further spread,” added FitzGerald. “Our Mobile COVID-19 Laboratory, which uses gold standard PCR technology and can visit the location of your choice for immediate service, will promote safe working practices, allow companies to demonstrate their commitment to their staff, and facilitate recovery of the UK economy.”


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
SARS-CoV-2 RT-PCR Assay
Reliance SARS-CoV-2 RT-PCR Assay Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Signs of multiple sclerosis show up in blood years before symptoms appear (Photo courtesy of vitstudio/Shutterstock)

Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset

Autoimmune diseases such as multiple sclerosis (MS) are thought to occur partly due to unusual immune responses to common infections. Early MS symptoms, including dizziness, spasms, and fatigue, often... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: A new study has identified patterns that predict ovarian cancer relapse (Photo courtesy of Cedars-Sinai)

Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse

High-grade serous ovarian carcinoma is the most lethal type of ovarian cancer, and it poses significant detection challenges. Typically, patients initially respond to surgery and chemotherapy, but the... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.